vs
Crescent Energy Co（CRGY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Crescent Energy Co的季度营收约是Revvity的1.1倍（$865.0M vs $772.1M），Revvity净利率更高（12.7% vs -1.0%，领先13.7%），Revvity同比增速更快（5.9% vs -1.2%），过去两年Crescent Energy Co的营收复合增速更高（14.7% vs 9.0%）
新月石油是中东地区成立最早、规模最大的私营上游油气企业，1971年成立，总部位于阿联酋沙迦酋长国，目前在阿联酋和伊拉克库尔德斯坦地区均有业务布局。截至2023年，公司已与伊拉克石油部签署三份为期20年的合同，助力伊拉克油气产业重建。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CRGY vs RVTY — 直观对比
营收规模更大
CRGY
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出7.0%
-1.2%
净利率更高
RVTY
高出13.7%
-1.0%
两年增速更快
CRGY
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $865.0M | $772.1M |
| 净利润 | $-8.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -6.2% | 14.5% |
| 净利率 | -1.0% | 12.7% |
| 营收同比 | -1.2% | 5.9% |
| 净利润同比 | 92.7% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRGYRVTY
| Q4 25 | $865.0M | $772.1M | ||
| Q3 25 | $866.6M | $698.9M | ||
| Q2 25 | $898.0M | $720.3M | ||
| Q1 25 | $950.2M | $664.8M | ||
| Q4 24 | $875.3M | $729.4M | ||
| Q3 24 | $744.9M | $684.0M | ||
| Q2 24 | $653.3M | $691.7M | ||
| Q1 24 | $657.5M | $649.9M |
净利润CRGYRVTY
| Q4 25 | $-8.7M | $98.4M | ||
| Q3 25 | $-9.5M | $46.7M | ||
| Q2 25 | $153.2M | $53.9M | ||
| Q1 25 | $-2.1M | $42.2M | ||
| Q4 24 | $-118.0M | $94.6M | ||
| Q3 24 | $-9.9M | $94.4M | ||
| Q2 24 | $37.5M | $55.4M | ||
| Q1 24 | $-24.2M | $26.0M |
毛利率CRGYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CRGYRVTY
| Q4 25 | -6.2% | 14.5% | ||
| Q3 25 | 3.6% | 11.7% | ||
| Q2 25 | 8.9% | 12.6% | ||
| Q1 25 | 18.1% | 10.9% | ||
| Q4 24 | -3.1% | 16.3% | ||
| Q3 24 | -1.0% | 14.3% | ||
| Q2 24 | 18.3% | 12.4% | ||
| Q1 24 | 20.4% | 6.8% |
净利率CRGYRVTY
| Q4 25 | -1.0% | 12.7% | ||
| Q3 25 | -1.1% | 6.7% | ||
| Q2 25 | 17.1% | 7.5% | ||
| Q1 25 | -0.2% | 6.4% | ||
| Q4 24 | -13.5% | 13.0% | ||
| Q3 24 | -1.3% | 13.8% | ||
| Q2 24 | 5.7% | 8.0% | ||
| Q1 24 | -3.7% | 4.0% |
每股收益（稀释后）CRGYRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.2M | $919.9M |
| 总债务越低越好 | $5.5B | — |
| 股东权益账面价值 | $5.2B | $7.3B |
| 总资产 | $12.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.07× | — |
8季度趋势，按日历期对齐
现金及短期投资CRGYRVTY
| Q4 25 | $10.2M | $919.9M | ||
| Q3 25 | $3.5M | $931.4M | ||
| Q2 25 | $3.1M | $991.8M | ||
| Q1 25 | $6.3M | $1.1B | ||
| Q4 24 | $132.8M | $1.2B | ||
| Q3 24 | $136.2M | $1.2B | ||
| Q2 24 | $778.1M | $2.0B | ||
| Q1 24 | $5.3M | $1.7B |
总债务CRGYRVTY
| Q4 25 | $5.5B | — | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.6B | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $1.7B | — |
股东权益CRGYRVTY
| Q4 25 | $5.2B | $7.3B | ||
| Q3 25 | $4.5B | $7.4B | ||
| Q2 25 | $4.5B | $7.6B | ||
| Q1 25 | $3.3B | $7.6B | ||
| Q4 24 | $3.1B | $7.7B | ||
| Q3 24 | $2.9B | $7.9B | ||
| Q2 24 | $2.1B | $7.9B | ||
| Q1 24 | $2.0B | $7.8B |
总资产CRGYRVTY
| Q4 25 | $12.4B | $12.2B | ||
| Q3 25 | $9.7B | $12.1B | ||
| Q2 25 | $9.9B | $12.4B | ||
| Q1 25 | $9.9B | $12.4B | ||
| Q4 24 | $9.2B | $12.4B | ||
| Q3 24 | $9.3B | $12.8B | ||
| Q2 24 | $7.5B | $13.4B | ||
| Q1 24 | $6.8B | $13.4B |
负债/权益比CRGYRVTY
| Q4 25 | 1.07× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $371.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CRGYRVTY
| Q4 25 | $371.0M | $182.0M | ||
| Q3 25 | $473.1M | $138.5M | ||
| Q2 25 | $499.0M | $134.3M | ||
| Q1 25 | $337.1M | $128.2M | ||
| Q4 24 | $384.4M | $174.2M | ||
| Q3 24 | $368.0M | $147.9M | ||
| Q2 24 | $286.9M | $158.6M | ||
| Q1 24 | $183.8M | $147.6M |
自由现金流CRGYRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率CRGYRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度CRGYRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率CRGYRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 3.26× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 7.64× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRGY
| Oil Reserves | $554.3M | 64% |
| Natural Gas Production | $182.6M | 21% |
| Natural Gas Liquids Reserves | $92.3M | 11% |
| Midstream And Other | $35.8M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
